Biovica International AB (publ) (BIOVIC-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has a cash flow conversion efficiency ratio of -0.670x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-17.20 Million ≈ $-1.85 Million USD) by net assets (Skr25.68 Million ≈ $2.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biovica International AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Biovica International AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biovica International AB (publ) balance sheet liabilities for a breakdown of total debt and financial obligations.
Biovica International AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovica International AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neola Medical AB
ST:NEOLA
|
-0.033x |
|
Phoenix New Media Limited
NYSE:FENG
|
N/A |
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
-0.028x |
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
STO Co. Ltd
KQ:098660
|
0.024x |
|
GEN Restaurant Group, Inc. Class A Common Stock
NASDAQ:GENK
|
-0.015x |
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
-0.151x |
|
THUNDER GOLD CORP.
F:Z25
|
N/A |
Annual Cash Flow Conversion Efficiency for Biovica International AB (publ) (2015–2025)
The table below shows the annual cash flow conversion efficiency of Biovica International AB (publ) from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see BIOVIC-B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | Skr43.21 Million ≈ $4.65 Million |
Skr-85.37 Million ≈ $-9.19 Million |
-1.976x | -66.65% |
| 2024-04-30 | Skr96.64 Million ≈ $10.40 Million |
Skr-114.58 Million ≈ $-12.33 Million |
-1.186x | -73.67% |
| 2023-04-30 | Skr138.64 Million ≈ $14.92 Million |
Skr-94.64 Million ≈ $-10.18 Million |
-0.683x | -62.51% |
| 2022-04-30 | Skr124.09 Million ≈ $13.35 Million |
Skr-52.13 Million ≈ $-5.61 Million |
-0.420x | -123.00% |
| 2021-04-30 | Skr182.66 Million ≈ $19.66 Million |
Skr-34.41 Million ≈ $-3.70 Million |
-0.188x | +40.54% |
| 2020-04-30 | Skr78.22 Million ≈ $8.42 Million |
Skr-24.78 Million ≈ $-2.67 Million |
-0.317x | +8.13% |
| 2019-04-30 | Skr52.10 Million ≈ $5.61 Million |
Skr-17.97 Million ≈ $-1.93 Million |
-0.345x | -70.81% |
| 2018-04-30 | Skr73.71 Million ≈ $7.93 Million |
Skr-14.88 Million ≈ $-1.60 Million |
-0.202x | -66.66% |
| 2017-04-30 | Skr91.55 Million ≈ $9.85 Million |
Skr-11.09 Million ≈ $-1.19 Million |
-0.121x | +67.11% |
| 2016-04-30 | Skr25.48 Million ≈ $2.74 Million |
Skr-9.38 Million ≈ $-1.01 Million |
-0.368x | -432.23% |
| 2015-04-30 | Skr8.32 Million ≈ $894.93K |
Skr922.00K ≈ $99.22K |
0.111x | -- |
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more